LifeSciences BC > member announcements > Qu Biologics Closes Private Financing of CDN$4 Million

Print Friendly

Qu Biologics Closes Private Financing of CDN$4 Million

Vancouver, British Columbia – April 12, 2016 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, announced it has closed a private financing of CDN$4 million bringing the total private equity capital raised to CDN$23 million to date, including more than CDN$7 million in the last 12 months.

Funds from this private equity financing will be used to continue to expand Qu Biologics’ clinical programs, including the initiation of a randomized, placebo-controlled trial in at least one cancer indication and adding to existing clinical trials in Crohn’s disease and ulcerative colitis. Qu Biologics completed enrollment of its randomized, placebo-controlled study in Crohn’s disease, expects to enroll a second group of participants into its open-label Phase 2 study in patients with ulcerative colitis later this year, and recently completed enrollment of its Phase 1/2 study in patients with recurrent non-small-cell lung cancer (NSCLC). Dr. Hal Gunn, CEO of Qu Biologics commented, “We are grateful for our investors’ support of our immunotherapy approach, as well as their continued confidence in our team. Rather than blocking or stimulating a single pathway, our treatments are designed to restore normal innate immune function. There is growing interest in the role of the innate immune system in chronic disease and as one of the first companies in this important field, we can continue to build upon the broad patent protection we have been granted for our treatments and their applications in cancer and inflammatory diseases.” Qu Biologics’ VP of Finance, E. Russell McAllister, added, “Due to the broad applicability and novel mechanism of action of Qu Biologics’ technology, we continue to be successful in raising capital at a time when the broader markets have been less favorable. Our investors appreciate the value of our innovative approach to immunotherapy and the potential that it holds for improving the health of people living with a wide variety of chronic diseases. The capital from this round will allow us to continue to expand and initiate a number of important clinical and non-clinical programs in 2016. We expect to have full results from our Crohn’s disease clinical study in the third quarter.”

 

For more information regarding this press release, contact:

Qu Biologics contact:

Julie Jang Director, Communications Qu Biologics Inc.

Phone:  604.734.1450 ext. 41491

Email: julie@qubiologics.com

 

ABOUT QU BIOLOGICS

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that are designed to stimulate an innate immune response in targeted organs, restoring normal immune function and reversing the chronic inflammation underlying many conditions including cancer and immune-related disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.quibd.com.

FIND OUT MORE